2024 年第 4 期 第 19 卷

不同剂量异烟肼治疗肺结核的临床效果及对患者肺功能和T淋巴细胞亚群的影响

Clinical effect of different doses of isoniazid in the treatment of pulmonary tuberculosis patients and its influence on lung function and T lymphocyte subsets

作者：王勇1张焕2安贺娟3郭燕4赵伟5刘荣5李振生6

英文作者：Wang Yong1 Zhang Huan2 An Hejuan3 Guo Yan4 Zhao Wei5 Liu Rong5 Li Zhensheng6

单位：1河北省胸科医院全科医学科，石家庄050000；2河北省胸科医院结核三科，石家庄050000；3河北省胸科医院结核四科，石家庄050000；4河北省胸科医院药学部，石家庄050000；5河北省盐山县人民医院呼吸科，沧州061399；6河北省胸科医院呼吸科，石家庄050000

英文单位：  1Department of General Practice Medicine Hebei Chest Hospital Shijiazhuang 050000 China; 2Department of Tuberculosis Three Branches Hebei Chest Hospital Shijiazhuang 050000 China; 3Department of Tuberculosis Four Branches Hebei Chest Hospital Shijiazhuang 050000 China; 4Department of Pharmacy Hebei Provincial Chest Hospital Shijiazhuang 050000 China; 5Department of Respiratory Yanshan People′s Hospital Hebei Province Cangzhou 061399 China; 6Department of Respiratory Hebei Chest Hospital Shijiazhuang 050000 China

关键词：肺结核；异烟肼；肺功能；T淋巴细胞亚群；临床效果

英文关键词：Pulmonarytuberculosis;Isoniazid;Lungfunction;Tlymphocytesubsets;Clinicaleffects

• 摘要：

• 目的 探讨不同剂量异烟肼治疗肺结核的临床效果及对患者肺功能、T淋巴细胞亚群的影响。方法 选取2020年6月至2022年6月河北省胸科医院收治的肺结核患者90例为研究对象，按照随机数字表法分为对照组和观察组，各45例。对照组在常规抗结核药物基础上予0.3 g/d异烟肼治疗，观察组在常规抗结核药物基础上予0.5 g/d异烟肼治疗，2组疗程均为6个月。比较2组临床疗效，评估患者肺功能及T淋巴细胞亚群变化情况。结果 观察组总有效率高于对照组（P<0.05）。治疗后，2组最大呼气流量、第1秒用力呼气容积均高于治疗前，且观察组均高于对照组［（7.8±1.4）L/s比（6.3±1.2）L/s、（1.48±0.28）L比（1.15±0.23）L］（均P<0.05）。治疗后，2组血清CD+3、CD+4、CD+4/CD+8比值均高于治疗前，且观察组均高于对照组，CD+8均低于治疗前，且观察组低于对照组（均P<0.05）。2组不良反应发生率比较差异无统计学意义（P＞0.05）。结论 不同剂量异烟肼治疗肺结核的临床效果不同，增加异烟肼剂量至0.5 g/d能够提升疗效，促进肺结核患者肺功能改善，提高免疫功能，且安全性较好。

• Objective To investigate the clinical effect of different doses of isoniazid in the treatment of pulmonary tuberculosis and its influence on lung function and T lymphocyte subsets in patients. Methods A total of 90 patients with pulmonary tuberculosis admitted to Hebei Chest Hospital from June 2020 to June 2022 were selected as the research objects. According to the random number table method, they were divided into the control group and the observation group, with 45 cases in each group. The control group was treated with 0.3 g/d isoniazid based on the conventional anti-tuberculosis drugs, while the observation group was treated with 0.5 g/d isoniazid based on the conventional anti-tuberculosis drugs, and both groups were treated for 6 months. The clinical efficacy of the two groups was compared, and the changes of lung function and T lymphocyte subsets were evaluated. Results The total effective rate of observation group was higher than that of control group (P<0.05). After treatment, the peak expiratory flow and forced expiratory volume in the first second of both groups were higher than those before treatment, and those in the observation group were higher than those in the control group［（7.8±1.4）L/s vs （6.3±1.2）L/s,（1.48±0.28）L vs （1.15±0.23）L］(all P<0.05). After treatment, the ratios of serum CD+3, CD+4, CD+4/CD+8 of both groups were higher than those before treatment, and those in the observation group were higher than those in the control group. The ratios of CD+8 of both groups were lower than those before treatment, and that in the observation group was lower than that in the control group (all P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Different doses of isoniazid have different clinical effects in the treatment of pulmonary tuberculosis patients. Increasing the dose of isoniazid to 0.5 g/d can improve the efficacy, promote the improvement of pulmonary function and immune function of patients with pulmonary tuberculosis, and has good safety.